PRO DEX INC Stock: price and directors' dealings · United States · SEC (Form 4)

About PRO DEX INC

Pro-Dex Inc. (ticker PDEX) is a niche U.S. medical-device and precision manufacturing company listed on the Nasdaq Capital Market, part of the NASDAQ market in the United States. For French-speaking investors, the company is best viewed as a specialized industrial healthcare supplier rather than a traditional pharmaceutical name. Pro-Dex says it has been in business for more than 40 years, with its corporate headquarters in Irvine, California. Over time, the business has evolved from a broader industrial footprint into a more focused platform centered on product development and contract manufacturing. Today, Pro-Dex’s core business is the design, development, and manufacture of autoclavable, battery-powered, and electric multi-function surgical drivers and shavers. These products are used primarily in the orthopedic, thoracic, and maxillofacial markets. The company also highlights proprietary torque-limiting software and sealing solutions, which support product differentiation and help create technical switching costs for customers. In addition to manufacturing, Pro-Dex offers engineering, quality, regulatory, and consulting services, making it a value-added outsourcing partner for OEM customers in the medical technology ecosystem. From a competitive standpoint, Pro-Dex is not a large diversified med-tech group. Its value proposition is based on specialization, engineering depth, manufacturing responsiveness, and the ability to work closely with major medical and dental product companies. The company states that it has collaborated with some of the world’s largest providers of medical and dental products, which suggests a client base that values reliability, technical customization, and regulatory discipline. Because of its size, revenue concentration is likely to remain an important analytical feature, with a limited number of customers accounting for a meaningful portion of sales. Geographically, Pro-Dex remains predominantly U.S.-anchored. The company’s headquarters are in Irvine, California, and it describes its outsourcing services as being provided nationwide and beyond. For investors in France, Belgium, or Switzerland, that means the name should be analyzed through the lens of a U.S. industrial healthcare supplier exposed to medical-device purchasing cycles, product launch timing, and the operational demands of regulated manufacturing. Recent developments have been material. In its fiscal year ended June 30, 2025, Pro-Dex reported strong top-line growth, driven mainly by its largest customer and sales of a next-generation handpiece. More importantly, in December 2025 the company announced a contract amendment extending its largest customer relationship by an additional three years, through December 31, 2028, with minimum purchase volumes for calendar 2026 and 2027. That extension improves medium-term revenue visibility and underscores the strategic importance of this client relationship. As with many small-cap NASDAQ names, investors also watch SEC insider Form 4 filings for additional sentiment signals from management and directors.